DGAP-News

Evotec and CHDI Foundation expand ongoing collaboration to fight Huntington's disease using Evotec's expanded capabilities and footprint - Seite 2

gene has a 50-50 chance of inheriting the mutation. As a result of carrying
the mutation, an individual's brain cells fail and die leading to cognitive
and physical impairments that, over the course of the disease,
significantly impair the individual's quality of life and ultimately cause
death. Symptoms of Huntington's disease, which generally develop in midlife
and become progressively more debilitating as time passes, can also develop
in infancy or old age. Once overt symptoms start, patients live for about
15 to 20 years. There is currently no way to delay the onset of symptoms or
slow the progression of Huntington's disease. It is estimated that the
disorder affects about 30,000 people in the United States and at least
150,000 others have a 50% risk of developing Huntington's disease at some
point.


ABOUT CHDI FOUNDATION, INC.
CHDI Foundation, Inc. is a privately-funded nonprofit biomedical research
organization that is exclusively dedicated to rapidly discovering and
developing therapies that slow the progression of Huntington's disease
(HD). Our scientists work closely with a network of more than 600
researchers in academic and industrial laboratories around the world in the
pursuit of these novel therapies, providing strategic scientific direction
to ensure that our common goals remain in focus. This helps bridge the
translational gap that often exists between academic and industrial
research pursuits and that adds costly delays to therapy development. In
its role as a collaborative enabler, CHDI seeks to bring the right partners
together to identify and address critical scientific issues and move drug
candidates to clinical evaluation as rapidly as possible. Our activities
extend from exploratory biology to the identification and validation of
therapeutic targets, and from drug discovery and development to clinical
studies and trials. More information about CHDI can be found at
www.chdifoundation.org.

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,